L. Steven Hoerter's Insider Trades & SAST Disclosures
L. Steven Hoerter's most recent trade in C4 Therapeutics Inc was a trade of 65,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Nov. 19, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern L. Steven Hoerter.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Steven L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2024 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| ORIC Pharmaceuticals Inc | Steven L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 25,600 | 25,600 | - | - | Stock Option (right to buy) | |
| Deciphera Pharmaceuticals Inc | Hoerter Steven L. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 298,100 | 298,100 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2023 | 62,500 | 103,427 (0%) | 0% | - | Common Stock | |
| Deciphera Pharmaceuticals Inc | L. Steven Hoerter | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.37 per share. | 12 Dec 2023 | 30,664 | 72,763 (0%) | 0% | 15.4 | 471,217 | Common Stock |
| ORIC Pharmaceuticals Inc | Steven L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.57 per share. | 21 Mar 2023 | 7,500 | 0 (0%) | 0% | 15.6 | 116,782 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 14 Feb 2023 | 30,045 | 7,500 (0%) | 0% | 16 | 480,720 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.11 per share. | 21 Mar 2022 | 3,150 | 37,545 (0%) | 0% | 9.1 | 28,697 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 415,000 | 415,000 | - | - | Stock Option (Right to Buy) | |
| ORIC Pharmaceuticals Inc | Steven L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 33,250 | 33,250 | - | - | Stock Option (right to buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.20 per share. | 18 Mar 2021 | 2,450 | 40,695 (0%) | 0% | 43.2 | 105,828 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.39 per share. | 18 Mar 2021 | 700 | 43,145 (0%) | 0% | 42.4 | 29,672 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 210,000 | 210,000 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 21 Jan 2021 | 1,078 | 43,845 (0%) | 0% | 25.4 | 27,381 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2021 | 1,078 | 395,735 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 187 | 396,813 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 20 Aug 2020 | 187 | 42,767 (0%) | 0% | 25.4 | 4,750 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 20 Jul 2020 | 188 | 42,580 (0%) | 0% | 25.4 | 4,775 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2020 | 188 | 397,000 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 187 | 397,188 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 18 Jun 2020 | 187 | 42,392 (0%) | 0% | 25.4 | 4,750 | Common Stock |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 188 | 397,375 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Steven L. Hoerter | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 28 May 2020 | 188 | 42,205 (0%) | 0% | 25.4 | 4,775 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges